Business Description
Charmacy Pharmaceutical Co Ltd
ISIN : CNE1000023D6
Share Class Description:
HKSE:02289: Shs -H- Reg STotal Employee Number:
847Compare
Compare
Traded in other countries / regions
02289.Hong Kong IPO Date
2015-12-14Description
Charmacy Pharmaceutical Co Ltd operates within the pharmaceutical distribution industry, with a primary focus on the distribution of pharmaceutical products. The principal business activities encompass the wholesale of pharmaceuticals and related services, along with road transportation and cargo warehousing. The company's distribution network covers Southern China and surrounding areas including Fujian province. All the group's operations are located in China.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.36 | |||||
Equity-to-Asset | 0.16 | |||||
Debt-to-Equity | 3.39 | |||||
Debt-to-EBITDA | 13.48 | |||||
Interest Coverage | 2.62 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 1.46 | |||||
Beneish M-Score | -2.79 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 1.3 | |||||
3-Year EBITDA Growth Rate | -6.7 | |||||
3-Year EPS without NRI Growth Rate | -19.4 | |||||
3-Year FCF Growth Rate | 94.4 | |||||
3-Year Book Growth Rate | 0.8 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 0.29 | |||||
9-Day RSI | 4.42 | |||||
14-Day RSI | 12.64 | |||||
3-1 Month Momentum % | 25.43 | |||||
6-1 Month Momentum % | 25.86 | |||||
12-1 Month Momentum % | 25 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.09 | |||||
Quick Ratio | 0.84 | |||||
Cash Ratio | 0.23 | |||||
Days Inventory | 64.84 | |||||
Days Sales Outstanding | 98.7 | |||||
Days Payable | 37.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 6.25 | |||||
Dividend Payout Ratio | 0.79 | |||||
Forward Dividend Yield % | 6.25 | |||||
5-Year Yield-on-Cost % | 6.25 | |||||
Shareholder Yield % | -47.21 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 7.75 | |||||
Operating Margin % | 3.4 | |||||
Net Margin % | 1.06 | |||||
EBITDA Margin % | 3.55 | |||||
FCF Margin % | 6.05 | |||||
OCF Margin % | 6.22 | |||||
ROE % | 7.67 | |||||
ROA % | 1.28 | |||||
ROIC % | 4.91 | |||||
3-Year ROIIC % | 5.34 | |||||
ROC (Joel Greenblatt) % | 7.26 | |||||
ROCE % | 18.22 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 11.68 | |||||
PE Ratio without NRI | 8.84 | |||||
Shiller PE Ratio | 10.19 | |||||
Price-to-Owner-Earnings | 8.28 | |||||
PEG Ratio | 1.25 | |||||
PS Ratio | 0.12 | |||||
PB Ratio | 0.87 | |||||
Price-to-Tangible-Book | 0.99 | |||||
Price-to-Free-Cash-Flow | 2.04 | |||||
Price-to-Operating-Cash-Flow | 1.98 | |||||
EV-to-EBIT | 16.14 | |||||
EV-to-EBITDA | 12.54 | |||||
EV-to-Revenue | 0.45 | |||||
EV-to-FCF | 7.37 | |||||
Price-to-GF-Value | 0.66 | |||||
Price-to-Projected-FCF | 0.67 | |||||
Price-to-Median-PS-Value | 0.69 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.58 | |||||
Price-to-Graham-Number | 0.62 | |||||
| Price-to-Net-Current-Asset-Value | 2.48 | |||||
Earnings Yield (Greenblatt) % | 6.2 | |||||
FCF Yield % | 49.05 | |||||
Forward Rate of Return (Yacktman) % | 16.01 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Charmacy Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 4,818.671 | ||
| EPS (TTM) (HK$) | 0.471 | ||
| Beta | -0.7688 | ||
| 3-Year Sharpe Ratio | 0.07 | ||
| 3-Year Sortino Ratio | 0.14 | ||
| Volatility % | 55 | ||
| 14-Day RSI | 12.64 | ||
| 14-Day ATR (HK$) | 0.0486 | ||
| 20-Day SMA (HK$) | 5.865 | ||
| 12-1 Month Momentum % | 25 | ||
| 52-Week Range (HK$) | 4.3 - 7.4 | ||
| Shares Outstanding (Mil) | 108 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Charmacy Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Charmacy Pharmaceutical Co Ltd Stock Events
| Event | Date | Price (HK$) | ||
|---|---|---|---|---|
| HKD 0.343531 Cash Dividend | 2026-05-27 | 5.82 (+0.00%) | ||
| HKD 0.488950 Cash Dividend | 2025-05-26 | 7.70 (+0.00%) |
Show
Entries
Charmacy Pharmaceutical Co Ltd Frequently Asked Questions
What is Charmacy Pharmaceutical Co Ltd(HKSE:02289)'s stock price today?
The current price of HKSE:02289 is HK$5.50. The 52 week high of HKSE:02289 is HK$7.40 and 52 week low is HK$4.30.
When is next earnings date of Charmacy Pharmaceutical Co Ltd(HKSE:02289)?
The next earnings date of Charmacy Pharmaceutical Co Ltd(HKSE:02289) is .
Does Charmacy Pharmaceutical Co Ltd(HKSE:02289) pay dividends? If so, how much?
The Dividend Yield %  of Charmacy Pharmaceutical Co Ltd(HKSE:02289) is 6.25% (As of Today), Highest Dividend Payout Ratio of Charmacy Pharmaceutical Co Ltd(HKSE:02289) was 1.01. The lowest was 0.37. And the median was 0.78. The  Forward Dividend Yield % of Charmacy Pharmaceutical Co Ltd(HKSE:02289) is 6.25%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Charmacy Pharmaceutical Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers